| 000 | 01884 a2200481 4500 | ||
|---|---|---|---|
| 005 | 20250515012041.0 | ||
| 264 | 0 | _c20110915 | |
| 008 | 201109s 0 0 ita d | ||
| 022 | _a0048-7449 | ||
| 024 | 7 |
_a10.4081/reumatismo.2005.4s.3 _2doi |
|
| 040 |
_aNLM _beng _cNLM |
||
| 100 | 1 | _aValesini, G | |
| 245 | 0 | 0 |
_a[Effects of TNF antagonists on immune and neuroendocrine system]. _h[electronic resource] |
| 260 |
_bReumatismo _c2005 |
||
| 300 |
_a3-7 p. _bdigital |
||
| 500 | _aPublication Type: Comparative Study; English Abstract; Journal Article; Review | ||
| 650 | 0 | 4 | _aAdalimumab |
| 650 | 0 | 4 |
_aAntibodies, Anti-Idiotypic _xbiosynthesis |
| 650 | 0 | 4 |
_aAntibodies, Monoclonal _xadverse effects |
| 650 | 0 | 4 | _aAntibodies, Monoclonal, Humanized |
| 650 | 0 | 4 |
_aAntirheumatic Agents _xadverse effects |
| 650 | 0 | 4 | _aClinical Trials as Topic |
| 650 | 0 | 4 |
_aCrohn Disease _xdrug therapy |
| 650 | 0 | 4 | _aEtanercept |
| 650 | 0 | 4 | _aHumans |
| 650 | 0 | 4 |
_aHypothalamo-Hypophyseal System _xdrug effects |
| 650 | 0 | 4 |
_aImmune System _xdrug effects |
| 650 | 0 | 4 |
_aImmunoglobulin G _xadverse effects |
| 650 | 0 | 4 |
_aImmunosuppressive Agents _xadverse effects |
| 650 | 0 | 4 | _aInfliximab |
| 650 | 0 | 4 |
_aLymphocyte Subsets _xdrug effects |
| 650 | 0 | 4 |
_aMacrophage Activation _xdrug effects |
| 650 | 0 | 4 |
_aNeurosecretory Systems _xdrug effects |
| 650 | 0 | 4 |
_aPituitary-Adrenal System _xdrug effects |
| 650 | 0 | 4 |
_aPsoriasis _xdrug therapy |
| 650 | 0 | 4 |
_aReceptors, Tumor Necrosis Factor _xtherapeutic use |
| 650 | 0 | 4 |
_aReceptors, Tumor Necrosis Factor, Type II _xantagonists & inhibitors |
| 650 | 0 | 4 |
_aRheumatic Diseases _xdrug therapy |
| 650 | 0 | 4 |
_aTumor Necrosis Factor-alpha _xantagonists & inhibitors |
| 700 | 1 | _aCutolo, M | |
| 773 | 0 |
_tReumatismo _gvol. 57 _gno. 4 Suppl _gp. 3-7 |
|
| 856 | 4 | 0 |
_uhttps://doi.org/10.4081/reumatismo.2005.4s.3 _zAvailable from publisher's website |
| 999 |
_c16003599 _d16003599 |
||